Compare · BRSH vs WST
BRSH vs WST
Side-by-side comparison of Bruush Oral Care Inc. (BRSH) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRSH and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $22.59B.
- WST has hit the wire 5 times in the past 4 weeks while BRSH has been quiet.
- WST has more recent analyst coverage (17 ratings vs 0 for BRSH).
- Company
- Bruush Oral Care Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.09+11.41%
- $320.02+1.78%
- Market cap
- -
- $22.59B
- 1M return
- -
- -0.60%
- 1Y return
- -
- +42.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 17
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest BRSH
- SEC Form 6-K filed by Bruush Oral Care Inc.
- 12 Consumer Staples Stocks Moving In Wednesday's Intraday Session
- Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Why Doximity Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- Shares of consumer staples stocks are trading higher possibly amid sympathy with Walmart after the company reported better-than-expected Q1 financial results.
- Why Fluent Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
- Brüush Oral Care Receives Additional Delisting Threat Over Audit Committee Non-Compliance
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)